Department of Ophthalmology, Tumor Center Western Germany, Essen University Hospital; Department of Internal Medicine (Tumor Research), Tumor Center Western Germany, Essen University Hospital; Department of Pediatrics III, Tumor Center Western Germany, Essen University Hospital; Institute for Human Genetics, Tumor Center Western Germany, Essen University Hospital.
Dtsch Arztebl Int. 2018 Feb 16;115(7):106-111. doi: 10.3238/arztebl.2018.0106.
Recent years have seen major changes in the diagnosis and treatment of solid intraocular tumors, mainly owing to an improved molecular biological understanding of their pathogenesis, new therapeutic approaches for the local treatment of tumors in children, and long-term follow-up observations in clinical trials.
This review is based on pertinent publications retrieved by a selective search in PubMed.
Retinoblastoma is the most common type of primary intraocular tumor, with approximately 8000 new cases per year around the world, while malignant melanoma of the uvea is the most common primary intraocular tumor in adults, with approximately 7000 new cases per year around the world. Intraocular metastases of malignant tumors are ten times more common, in terms of incidence, than primary intraocular tumors and are therefore the most common intraocular tumors overall. Improved methods of intraocular biopsy, diagnostic imaging, and molecular genetic investigation have led to steady improvement in clinical and predictive diagnostic assessment. In the treatment of retinoblastoma, local techniques including brachytherapy and intra-arterial and intravitreal chemotherapy play a prominent role. Prognostic molecular-genetic testing now enables the highly selective identification of uveal melanomas that have a high potential to metastasize. Cutaneous and uveal melanomas differ both in their clinical behavior and in their basic biological features; to date, effective systemic treatment has been established for melanoma of the skin, but not for metastatic melanoma of the uvea. Intraocular metastases are common and often the initial manifestation of an extraocular tumor, particularly lung cancer.
Modern diagnostic and therapeutic concepts for intraocular tumors can only be implemented through the close interdisciplinary collaboration of ophthal - mologists, oncologists, radiologists, radiotherapists, pathologists, and human geneticists.
近年来,实体眼内肿瘤的诊断和治疗发生了重大变化,主要归因于对其发病机制的分子生物学认识的提高、儿童肿瘤局部治疗的新治疗方法,以及临床试验的长期随访观察。
本综述基于在 PubMed 中进行选择性搜索检索到的相关出版物。
视网膜母细胞瘤是最常见的原发性眼内肿瘤,全球每年约有 8000 例新病例,而葡萄膜恶性黑色素瘤是成年人最常见的原发性眼内肿瘤,全球每年约有 7000 例新病例。恶性肿瘤的眼内转移在发病率方面是原发性眼内肿瘤的 10 倍,因此是最常见的眼内肿瘤。眼内活检、诊断成像和分子遗传学研究方法的改进导致了临床和预测性诊断评估的稳步提高。在视网膜母细胞瘤的治疗中,局部技术,包括近距离放射治疗、动脉内和玻璃体内化疗,发挥着重要作用。预后分子遗传学检测现在能够高度选择性地识别具有高转移潜力的葡萄膜黑色素瘤。皮肤和葡萄膜黑色素瘤在临床行为和基本生物学特征上均存在差异;迄今为止,已为皮肤黑色素瘤建立了有效的全身治疗方法,但尚未为葡萄膜黑色素瘤的转移性黑色素瘤建立有效的全身治疗方法。眼内转移很常见,通常是眼外肿瘤的首发表现,尤其是肺癌。
眼内肿瘤的现代诊断和治疗概念只能通过眼科医生、肿瘤学家、放射科医生、放射治疗师、病理学家和人类遗传学家的密切跨学科合作来实现。